Compare Heron Therapeutics Inc (HRTX) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Alliant Energy Corporation — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Alliant Energy Corporation trades at $65.88 (market cap $16.99B). The key difference: Alliant Energy Corporation is far larger — about 249.8× Heron Therapeutics Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Alliant Energy Corporation for 64 Days on average.
| HRTX | LNT | |
|---|---|---|
Market Cap | $68.01M | $16.99B |
Volume | 1,891,941 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $1.49 | $78.03 |
52-Week Low | $0.27 | $63.21 |
Typical Hold Time | 35 Days | 64 Days |
Enterprise Value | $174.75M | $29.08B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
LNT trades at $65.84, up 0.97% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters and maintains solid profitability with an 18.45% net margin. Analyst consensus is bullish with a $77 price target, and institutional interest remains high, evidenced by recent large purchases.
LNT's outlook is supported by a $13.4 billion capital investment plan and growing data center demand, though rising debt levels and competitive pressures present risks. The stock offers a defensive income stream with a consistent dividend, but investors should monitor execution of growth initiatives amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
